The $4.85 billion Vioxx settlement announced last week is bolstering hopes of another set of plaintiffs: investors and employees who filed securities, derivative and ERISA suits against the company.
Plaintiffs in 10 cases, consolidated in New Jersey’s federal district court, claim they were financially harmed by Merck & Co.’s marketing of a dangerous drug, and their attorneys say the product liability settlement shows the damages were high.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
